Breaking News

You are here » Indian-Commodity  :  Equity & Shares  :  Glenmark gains with arm getting approval from USFDA for Sevelamer Hydrochloride Tablets

11-Feb2019

Glenmark gains with arm getting approval from USFDA for Sevelamer Hydrochloride Tablets

Glenmark Pharmaceuticals is currently trading at Rs. 619.60, up by 5.15 points or 0.84% from its previous closing of Rs. 614.45 on the BSE.

The scrip opened at Rs. 614.55 and has touched a high and low of Rs. 623.50 and Rs. 614.00 respectively. So far 4450 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 711.55 on 10-Sep-2018 and a 52 week low of Rs. 483.60 on 30-May-2018.

Last one week high and low of the scrip stood at Rs. 664.45 and Rs. 612.00 respectively. The current market cap of the company is Rs. 17337.82 crore.

The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 39.20% and 14.26% respectively.

Glenmark Pharmaceuticals – subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Sevelamer Hydrochloride Tablets, 400 mg and 800 mg, a generic version of Renagel Tablets, 400 mg and 800 mg, of Genzyme Corporation.

According to IQVIA sales data for the 12 month period ending December 2018, the Renagel Tablets, 400 mg and 800 mg market achieved annual sales of approximately $102.1 million.

The company's current portfolio consists of 149 products authorized for distribution in the US market place and 53 ANDA's pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).


Related News

View all news

United Bank of India shines on getting nod to raise Rs 1,500 crore by various means

United Bank of India is currently trading at Rs. 11.05, up by 0.50 points or 4.74% from its previous closing of Rs. 10.55 on the BSE.The scrip opened at Rs. 10.85 and has touched a high and low of Rs.......

Pondy Oxides & Chemicals gains on planning to merge Meloy Metals with itself

Pondy Oxides & Chemicals is currently trading at Rs. 319.80, up by 1.85 points or 0.58% from its previous closing of Rs. 317.95 on the BSE.The scrip opened at Rs. 317.80 and has touched a high......

Venky's slips on reporting 41.52% fall in Q4 net profit

Venky's  (India) is currently trading at Rs. 1766.00, down by 56.15 points or 3.08% from its previous closing of Rs. 1822.15 on the BSE.The scrip opened at Rs. 1817.00 and has touched a high and......

Top News

View all news

SRF, NIIT Technologies and United Bank of India to see some action today

SRF has entered into a definitive agreement to sell its Engineering Plastics Business to DSM, the Life Sciences and Materials Sciences Company in an all-cash transaction, amounting to Rs 320 crore. The......

NIIT Technologies concludes sale of 88.99% stake in ESRI India Technologies

NIIT Technologies has concluded the sale of 88.99% equity shares in ESRI India Technologies, India to Environment Systems Research Institute Inc., USA. Consequent to above sale, ESRI India Technologies,......

United Bank of India to raise Rs 1,500 crore by various means

United Bank of India has received approval to raise equity capital not exceeding Rs 1,500 crore in one or more tranches during the financial year by way of Qualified Institutions Placement, Public Issue,......